These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 28476823

  • 1. Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
    Sletten ET, Arnes M, Lysa LM, Moe BT, Straume B, Orbo A.
    Anticancer Res; 2017 May; 37(5):2529-2536. PubMed ID: 28476823
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
    Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK.
    Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system.
    Orbo A, Arnes M, Pettersen I, Larsen K, Hanssen K, Moe B.
    Acta Obstet Gynecol Scand; 2010 Nov; 89(11):1438-46. PubMed ID: 20955098
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of diagnostic accuracy between endometrial curettage and pipelle aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group Study (KGOG 2019).
    Kim MK, Seong SJ, Lee TS, Ki KD, Lim MC, Kim YH, Kim K, Joo WD.
    Jpn J Clin Oncol; 2015 Oct; 45(10):980-2. PubMed ID: 26206899
    [Abstract] [Full Text] [Related]

  • 9. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.
    Vereide AB, Kaino T, Sager G, Ørbo A, Scottish Gynaecological Clinical Trials Group.
    Gynecol Oncol; 2005 Jun; 97(3):740-50. PubMed ID: 15885761
    [Abstract] [Full Text] [Related]

  • 10. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A, Travaglino A, Saccone G, Mollo A, De Placido G, Insabato L, Zullo F.
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [Abstract] [Full Text] [Related]

  • 11. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.
    Orbo A, Vereide A, Arnes M, Pettersen I, Straume B.
    BJOG; 2014 Mar; 121(4):477-86. PubMed ID: 24286192
    [Abstract] [Full Text] [Related]

  • 12. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D, Antoniou G, Karakitsos P, Kalogirou O, Antoniou D, Giannikos L.
    Int J Fertil Menopausal Stud; 1996 Mar; 41(6):522-7. PubMed ID: 9010746
    [Abstract] [Full Text] [Related]

  • 13. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
    Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, Gupta JK.
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.
    Sletten ET, Arnes M, Vereide AB, Ørbo A.
    Anticancer Res; 2018 May; 38(5):2883-2889. PubMed ID: 29715112
    [Abstract] [Full Text] [Related]

  • 16. Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study.
    Gallos ID, Devey J, Ganesan R, Gupta JK.
    Gynecol Oncol; 2013 Jul; 130(1):58-63. PubMed ID: 23603367
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Levonorgestrel-Releasing Intrauterine System vs. Oral Progestins for Treatment of Endometrial Hyperplasia.
    Liegl S.
    Am Fam Physician; 2016 Jun 01; 93(11):948-9. PubMed ID: 27281840
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.